Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

Exclusion Criteria

• •hepatic and renal diseases and/or pathological findings, which might interfere with pharmacokinetics and pharmacodynamics of the study medication
• •gastrointestinal diseases and/or pathological findings (e.g. stenoses), which might interfere with pharmacokinetics and pharmacodynamics of the study medication
• •subjects with existing dysfunction in regulation of glucose metabolism, e.g. deficiency of glucose-6-phosphate dehydrogenase (Glc-6-P DHG) and/ or pathological findings
• •subjects with alcohol and/ or drug dependence and a alcohol consumption more than 20 g alcohol/ day
• •excessive smoking (more than 10 cigarettes or equivalents/ day)
• •subjects with positive finding of HBsAG, HIV and/ or drugs
• •subjects being on a diet (inclusive special or uniform nutritional habits, e.g. vegetarians or undercaloric diet)
• •strong coffee and/ or tea consumption (≥ 1 liter a day)
• •subjects suspected or known not to follow instructions
• •subjects who are unable to understand written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
• •subjects liable to orthostatic dysregulation, fainting, or blackout
• •subjects who took part in other clinical trials in the last 3 months (blocking time due to another clinical trial with investigational products)
• •acute illness less than 14 d in the past
• •blood donation within the last 3 months
• •any medication within 4 weeks prior to the intended first administration of the study medication which might influence functions of the gastrointestinal tract (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists, proton pump inhibitors, anticholinergics)
• •any other medication within 2 weeks prior to the first administration of the study medication or less than 10-time the half-live of the respective drug
• •intake of grapefruit containing food or beverages and poppy seeds containing products 14 d prior to the first drug administration until the last blood sampling of the study